Abstract: Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells, providing an environment in which the injured tissue can be regenerated with the foreign cells.
Type:
Application
Filed:
November 17, 2009
Publication date:
March 25, 2010
Applicant:
XIMEREX, INC.
Inventors:
William E. Beschorner, Carlos E. Sosa, Scott C. Thompson
Abstract: Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells, providing an environment in which the injured tissue can be regenerated with the foreign cells.
Type:
Grant
Filed:
September 17, 2003
Date of Patent:
December 1, 2009
Assignee:
Ximerex, Inc.
Inventors:
William E. Beschorner, Carlos E. Sosa, Scott C. Thompson
Abstract: Transgenic mammals which express human preproinsulin, methods and reagents for producing the transgenic mammals, and therapeutic methods of providing patients with insulin and C-peptide using tissues and cells from the transgenic mammals.
Type:
Application
Filed:
April 11, 2006
Publication date:
August 27, 2009
Applicant:
XIMEREX, inc.
Inventors:
William Beschorner, Patrick E. Kudlacek
Abstract: Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells, providing an environment in which the injured tissue can be regenerated with the foreign cells.
Type:
Application
Filed:
September 17, 2003
Publication date:
June 14, 2007
Applicant:
XIMEREX, INC.
Inventors:
William Beschorner, Carlos Sosa, Scott Thompson
Abstract: This invention provides a method for developing immune tolerance in xenogeneic organ graft recipients, in which lympho-hematopoietic cells from an intended organ graft recipient are differentiated within a xenogeneic surrogate, such as a fetal animal. After birth of the surrogate, the matured lympho-hematopoietic cells containing antigen specific regulatory cells, including suppressor cells, veto cells, select B cells, anti-idiotype antibodies, and other related factors responsible for antigen specific tolerance in a surrogate animal are reintroduced into the intended organ graft recipient, in conjunction with an organ transplant or a tissue transplant from the xenograft surrogate. The invention also provides an organ graft repopulated with cells from the intended organ graft recipient produced in a surrogate animal.